Related Experiment Video

Updated: Jul 8, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Development of small-molecule inhibitors of Raf

Shuhong Wu1, Wei Guo, Bingliang Fang

  • 1Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Recent Patents on Anti-Infective Drug Discovery
|January 29, 2008
PubMed

Insights

Small molecule Raf inhibitors show promise for treating cancer and other diseases. Bay 43-9006, a Raf inhibitor, demonstrates clinical benefit in cancer trials with minimal toxicity, suggesting broad therapeutic potential.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Raf proteins are crucial in the Ras/Raf/MEK/ERK signaling pathway.
  • This pathway is implicated in cancer, viral infections, and neurodegenerative diseases.
  • Gain-of-function mutations in Raf genes are common in various cancers.

Purpose of the Study:

  • To investigate the therapeutic potential of small-molecule Raf inhibitors.
  • To evaluate Raf as a target for anticancer drug development.
  • To explore applications beyond cancer therapy.

Main Methods:

  • Review of literature and patent applications for small-molecule Raf inhibitors.
  • Analysis of clinical trial data for compounds like Bay 43-9006.
  • Preclinical evaluation of inhibitors for various diseases.

Main Results:

  • Numerous small-molecule Raf inhibitors have been developed.
  • Bay 43-9006 has undergone extensive clinical trials for cancer, showing benefit and low toxicity.
  • Preclinical studies indicate potential for treating viral infections, neurodegeneration, and inflammatory conditions.

Conclusions:

  • Small-molecule Raf inhibitors represent a promising therapeutic strategy.
  • Bay 43-9006 demonstrates efficacy and safety in cancer treatment.
  • Raf inhibitors may offer broad therapeutic applications across multiple disease areas.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rab Proteins01:14

Rab Proteins

Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...